The use of the antioxidant tirilazad mesylate in human liver transplantation: Is there a therapeutic benefit?

Intensive Care Medicine

Volumn 25, Issue 6, 1999, Pages 616-619

  Plochl W ^a,b   Krenn, C G ^a   Pokorny, H ^a   Pezawas, L ^a   Pezawas, T ^a   Steltzer, H ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Ischaemia reperfusion injury; Liver transplantation; Malonaldehyde; Tirilazad mesylate

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE; CHOLINESTERASE; MALONALDEHYDE; TIRILAZAD;

ADULT; ARTICLE; BLOOD LEVEL; CHOLINESTERASE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; INTENSIVE CARE UNIT; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; LIVER FUNCTION; LIVER ISCHEMIA; LIVER TRANSPLANTATION; MALE; OUTCOMES RESEARCH; OXIDATIVE STRESS; POSTOPERATIVE PERIOD; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY; STATISTICAL ANALYSIS;

ANTIOXIDANTS; FEMALE; HUMANS; LIVER TRANSPLANTATION; MALE; MALONDIALDEHYDE; PREGNATRIENES; REPERFUSION INJURY; TREATMENT OUTCOME;

EID: 0033030383     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001340050912     Document Type: Article

References (11)

1. 1. Biasi F, Bosco M, Chiappino I, Chiarpotto E, Lanfranco G, Ottobrelli A, Massano G, Donadio PP, Vaj M, Andorno E, Rizzetto M, Salizzoni M, Poli G (1995) Oxidative damage in human liver transplantation. Free Radic Biol Med 19: 311-317
2. 2. Buttgereit F, Hiepe F, Burmester GR (1997) Das therapeutische Potential der Lazaroide (21-Aminosteroide). Dtseh Med Wochenschr 122: 1363-1367
3. 3. Wang Y, Mathews WR, Guido DM, Jaeschke H (1996) The 21-aminosteroid tirilazad mesylate protects against liver injury via membrane stabilization not inhibition of lipid peroxidation. J Pharmacol Exp Ther 277: 714-720
4. 4. Cosenza CA, Cramer DV, Cunneen SA, Tuso PJ, Wang HK, Makowka L (1994) Protective effect of the lazaroid U74006F in cold ischemia-reperfusion injury of the liver. Hepatology 19: 418-425
5. 5. Rabl H, Khoschsorur G, Colombo T, Tatzber F, Esterbauer H (1992) Human plasma lipid peroxide levels show a strong transient increase after successful revascularization operations. Free Radic Biol Med 13: 281-288
6. 6. Kassell NF, Haley EC Jr, Apperson-Hansen C, Alves WM (1996) Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia and New Zealand. J Neurosurg 84: 221-228
7. 7. The RANTTAS Investigators (1996) A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). Stroke 27: 1453-1458
8. 8. Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, Fehlings M, Herr DL, Hitchon PW, Marshall LF, Nockels RP, Pascale V, Perot PL Jr, Piepmeier J, Sonntag VKH, Wagner F, Wilberger JE, Winn HR, Young W (1997) Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. JAMA 277: 1597-1604
9. 9. Jacobsson J, Sundberg R, Rilo HLR, Gasbarrini A, Starzl TE, Van Thiel D (1993) Protective effects of the lazaroid U74500A and lidoflazine on liver preservation with UW solution. Transpl Int 6: 281-284
10. 10. Fleishaker JC, Hulst LK, Peters GR (1994) Multiple-dose tolerability and pharmacokinetics of tirilazad mesylate at doses of up to 10 mg/kg/day administered over 5-10 days in healthy volunteers. Int J Clin Pharmacol Ther 32: 223-230
11. 11. Bianchi G, Marchesini G, Fabbri A, Ronchi M, Chianese R, Grossi G (1997) Lipoperoxide plasma levels in patients with liver cirrhosis. Hepato-gastroenterology 44: 784-788